Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2948 | Placebo Ribavirin Wiki | 1.00 |
| drug2942 | Placebo Hydroxychloroquine Wiki | 1.00 |
| drug2945 | Placebo Nitazoxanide Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a phase I, open-label, dose-escalation clinical study to evaluate the safety, tolerability and immunogenicity of 3 ascending doses of UB-612 COVID-19 vaccine in healthy adults, aged from 20 to 55 years old.
Description: Occurrence of adverse reactions within 7 days after vaccination Percentage of subjects with ≥ Grade 3 adverse events within 7 days after vaccination
Measure: Safety of UB-612 vaccine Time: 7 days following vaccinationDescription: Occurrence of adverse events (AEs) till Day 56 Occurrence of serious adverse events (SAEs) till Day 56
Measure: Safety Time: Day 0 to Day 56Description: Occurrence of serious adverse events during the whole follow-up period
Measure: Safety Time: Day 29 to Day 196Description: Occurrence of adverse events of special interest during the study period
Measure: Safety Time: Day 0 to Day 196Description: Geometric mean titer (GMT) of antigen-specific antibody (Anti-S1-RBD)
Measure: Immunogenicity Time: Day 14, 28, 42, 56, 112, and 196Description: Seroconversion rate (SCR) of antigen-specific antibody (Anti-S1-RBD)
Measure: Immunogenicity Time: Day 14, 28, 42, 56, 112, and 196Description: Geometric mean fold increase of antigen-specific antibody (Anti-S1-RBD)
Measure: Immunogenicity Time: Day 14, 28, 42, 56, 112, and 196Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports